---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-008948"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2024-12-23T23:59:59+00:00"
generated_at: "2026-05-28T23:44:38.136574+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tivic Health reports >65% DTC gross margin, advances VNS program with Feinstein Institute

## Summary
- ClearUP 2.0 launched; McKesson & Cardinal Health partnerships accelerating; customer reviews 4.4 stars; defect returns down.
- D2C gross margin over 65% (vs <28% in 2023); net operating loss reduced more than 30%.
- VNS pilot study with Feinstein Institute showed best-in-industry results; second study fully enrolled, data expected next year.
- Targeting $30B+ annual market opportunity in non-invasive VNS; 16 issued patents, 10 pending internationally.
- Plans disease-specific clinical trials in 2025, working to regain Nasdaq compliance.

## SEC filing metadata
- accession: 0001683168-24-008948
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2024-12-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316824008948/0001683168-24-008948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316824008948/tivic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-008948
- JSON: https://secwatch.observer/filing/0001683168-24-008948.json
- Plain text: https://secwatch.observer/filing/0001683168-24-008948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.